UBS Maintains Neutral on Molina Healthcare, Raises Price Target to $380
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo has maintained a Neutral rating on Molina Healthcare (NYSE:MOH) and increased the price target from $350 to $380.
December 21, 2023 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has maintained a Neutral rating on Molina Healthcare and raised the price target to $380, indicating a positive outlook on the company's future performance.
The increase in price target by UBS suggests an improved outlook on Molina Healthcare's performance, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100